dydrogesterone / Generic mfg. - LARVOL DELTA

PRO-MHT: Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (clinicaltrials.gov) - P=N/A | N=200 | Not yet recruiting | Sponsor: Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital

New trial

PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study) (clinicaltrials.gov) - P=N/A | N=626 | Active, not recruiting | Sponsor: Mỹ Đức Hospital | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2025 ➔ Jun 2026

Enrollment closed • Trial primary completion date

Bardet-Biedl Syndrome Presenting with Abnormal Uterine Bleeding: A Case Report (ISGE 2026) - "Despite multiple treatment regimens—including combined oral contraceptives, norethisterone, dydrogesterone, and tranexamic acid—bleeding remained uncontrolled...Adjunctive therapy included vitamin D supplementation and metformin for insulin resistance... This case highlights the multifactorial nature of menstrual disturbances in Bardet-Biedl Syndrome, where structural uterine anomalies, metabolic and neuroendocrine abnormalities collectively contribute to abnormal uterine bleeding. Conventional treatments may be insufficient, necessitating an individualized management approach. Increased awareness of the gynecological manifestations of BBS is critical for improving the quality of life in affected individuals."

Case report • Clinical • Alzheimer's Disease • Ataxia • Bardet–Biedl Syndrome • Cognitive Disorders • Developmental Disorders • Endocrine Disorders • Genetic Disorders • Gynecology • Inherited Retinal Dystrophy • Movement Disorders • Obesity • Ophthalmology • Women's Health

Metabolic and Neurotransmitter Signatures of Depression Associated with Endometriosis: A Path Toward Phenotype-Oriented Therapeutic Strategies (ISGE 2026) - "Emotional disturbances may persist or worsen regardless of endometriosis treatment, highlighting the need for integrated psychological support. The choice of hormonal therapy should consider safety profiles: ovulation-suppressing agents (e.g., dienogest) may pose risks such as reduced bone mineral density and mood deterioration. Progestins that preserve ovulation (e.g., dydrogesterone) may offer a more balanced hormonal profile, better safety, and improved treatment adherence, ultimately enhancing therapeutic outcomes."

CNS Disorders • Depression • Endometriosis • Gynecology • Inflammation • Mood Disorders • Psychiatry • Women's Health

The clinical efficacy of dydrogesterone in the treatment of endometriosis: A follow-up study (ISGE 2026) - "Dydrogesterone treatment can significantly reduce dysmenorrhea in patients with endometriosis, control their cysts and cysts, and provide a treatment plan for patients with endometriosis who want to have children that can not only treat endomenorrhea but also provide natural fertility opportunities. Key words:Endometriosis,Dydrogesterone, Dysmenorrhea,Cyst size,fertility"

Clinical • Endometriosis • Gynecology • Women's Health

Our Experience Using Dydrogesterone in Two Novel Reproductive Protocols: Progestin-Primed Ovarian Stimulation with GnRH Agonist Trigger and Programmed-Ovulatory Frozen Embryo Transfer without hCG (ISGE 2026) - "Final oocyte maturation was triggered with GnRH agonist (triptorelin 0.2 mg). In the FET group, cycles were either natural proliferative phase or letrozole-modified (letrozole 2.5 or 5mg/day for 5 days)...These dydrogesterone-based protocols represent patient-friendly, low-intervention alternatives in assisted reproduction. Larger prospective studies are warranted."

Clinical • Hematological Malignancies

Endometrial protection during perimenopause and menopausal hormone therapy (ISGE 2026) - "In Hungary, micronized progesterone (administered orally or vaginally), dydrogesterone (administered orally), norethisterone acetate (administered orally), or medroxyprogesterone acetate (administered orally) are most commonly used in menopausal hormone therapy. Due to the wide variety of preparations and methods of administration, and considering that most studies still examine postmenopausal women and very few studies deal with perimenopausal hormone therapy, it is very difficult to assess each preparations optimal form of administration and dosage for endometrial protection while minimizing the risk of breast cancer and thromboembolic disease. We summarize the currently available data on the role of preparations used in Hungary in protecting the endometrium."

Breast Cancer • Endometrial Cancer • Long-acting Reversible Contraceptives • Solid Tumor

Pharmacological Treatment of Vasomotor and Psycho-Emotional Symptoms in Menopause (ISGE 2026) - "Interventions: During the menopausal transition, 31.1% of patients received HRT with estradiol (E2) 2 mg + cyproterone acetate. In postmenopause, 33.3% received E2 1 mg + dydrogesterone 5 mg... Combined hormonal and psychotropic therapy demonstrated superior efficacy compared to monotherapy in alleviating menopause-related symptoms and significantly improved patients' quality of life."

Heavy menstrual bleeding management in adolescents with von Willebrand disease: case report. (ISGE 2026) - "Hormonal treatment with dienogest/ethinylestradiol 2000/30 µg followed by dydrogesterone 10 mg was initiated for three months...She was treated with tranexamic acid and continues oral iron supplementation, with four courses of parenteral iron administered...Conclusions This case illustrates the need for a high index of suspicion for underlying bleeding disorders, such as type 1 von Willebrand disease, in adolescents presenting with severe menorrhagia. Early diagnosis allows for tailored management, including hormonal therapy, antifibrinolytic agents, and targeted hematologic treatment, thereby preventing severe complications such as iron deficiency anemia and the need for transfusions."

Case report • Clinical • Endometriosis • Gynecology • Hematological Disorders • Hemophilia • Thrombosis • Uterine Leiomyoma • Women's Health

Expulsion of a large polypoid endometrial mass in a young woman with polycystic ovary syndrome following sequential hormonal therapy: a case report (ISGE 2026) - "Case: A 20-year-old nulliparous woman with PCOS presented with the complaint of expelling a solid mass per vaginam on the second day of dydrogesterone intake, which she self-administered based on a prior prescription...For the preceding 3 months, she had used a COC supplemented with cyproterone acetate during the first 10 days of each cycle, with persistent amenorrhea... This case underscores the need for thorough evaluation before prescribing COCs, including the exclusion of preexisting intrauterine pathology, especially in PCOS patients. Continuous medical supervision—whether in person or via remote contact—during hormonal treatment is essential. Equally important is patient responsibility in adhering to follow-up recommendations and avoiding unsupervised hormonal use, which may lead to unexpected and potentially alarming outcomes."

Case report • Clinical • Polycystic Ovary Syndrome • Women's Health

The personalized approach for MHT selection according to women androgen status during menopausal transition (ISGE 2026) - "Dydrogesterone, being a highly selective and biologically similar progestogen, does not reduce baseline androgen levels. Thus, with oral MHT hormonal balance can be achieved."

Clinical • Women's Health

Challenges for Induced Ovulation of Infertile Women with Idiopathic Hypogonadotropic Hypogonadism (ISGE 2026) - "OI was initiated on days 2 - 5 of hormone withdrawal bleeding, implementing a low - dose step up protocal of human menopausal gonadotropin (HMG)...Post - ovulation (1 - 3 days), Luteal support was provided by supplementing 1-2mg/day of estradiol valerate(E2V) and 20-30mg/day of dydrogesterone(DYD) for 10-14 days...Therefore, continuous luteal support is indispensable until 12 weeks of gestation when the placental function fully assumes the role of luteal support. The findings of this study offer valuable references for clinicians treating IHH - related infertility"

Clinical • Endocrine Disorders • Genetic Disorders • Infertility • Sexual Disorders

Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis. (PubMed, EClinicalMedicine) - "Cyproterone acetate (CPA) was associated with increased meningioma risk (5 studies; 1047 exposed; pooled-OR 12.36 (95% CI: 7.47-20.45); I2: 73.8%; GRADE: moderate)...Chlormadinone acetate (CMA), nomegestrol acetate (NOMAC), promegestone, medrogestone, and desogestrel showed signals of increased risk (CMA 3 studies, 164-683 exposed; NOMAC 3, 171-969; promegestone 1, 83; medrogestone 1, 42; desogestrel 2, 115-287)...No signal was found for norgestrel, levonorgestrel, progesterone, dydrogesterone, or spironolactone; evidence for dienogest and hydroxyprogesterone was insufficient...Transparent patient information and careful clinical and, where appropriate, imaging follow-up are essential. None."

Journal • Retrospective data • Brain Cancer • Meningioma • Oncology • Solid Tumor

Gu Ben An Tai decoction combined with dydrogesterone for early threatened abortion secondary to spleen and kidney deficiency: a retrospective observational study. (PubMed, Contracept Reprod Med) - No abstract available

Journal • Observational data • Retrospective data

P450 engineering via structure-guided rational design achieves high C21-selectivity and bioconversion in steroid biosynthesis. (PubMed, Synth Syst Biotechnol) - "For instance, C21-hydroxylase catalyzes the conversion of progesterone (PRO) into 11-deoxycorticosterone (DOC, the precursor of cortisol and aldosterone)...Additionally, M6a-RhFRED L3 catalyzed the C21-hydroxylation of three steroid analogs (dydrogesterone, 16-dehydroprogesterone, and pregna-4,6-diene-3,20-dione), with selectivity reaching 98% and conversion rates exceeding 60%...This structural reorganization underscores the critical role of key residues in modulating regioselectivity, particularly the shift from C16α to C21 hydroxylation. This study not only provides an efficient biocatalyst for steroids C21-hydroxylation but also offers valuable insight for the rational engineering of the P450 enzymes."

Journal

Effectiveness of oral dydrogesterone compared to placebo in reducing the risk of preterm birth: a systematic review and meta-analysis. (PubMed, BMC Pregnancy Childbirth) - No abstract available

Journal • Retrospective data • Review

Dydrogesterone and Letrozole Combination for the Treatment of Endometriosis: A Mechanism-Based Therapeutic Approach. (PubMed, Obstet Gynecol Int) - "Our results revealed that the dydrogesterone-letrozole combination reduced the volume of endometriotic lesions, suppressed cell proliferation, and decreased inflammation relative to the disease control, with trends suggesting greater effects than those observed with individual agents or standard treatments such as dienogest and leuprolide. Based on existing literature, dydrogesterone is thought to counteract estrogen-driven endometrial proliferation through progesterone receptor activation, while letrozole is believed to reduce estrogen biosynthesis by inhibiting aromatase, which may collectively influence lesion growth and inflammatory processes. Additional long-term studies are warranted to thoroughly assess the safety profile, clinical effectiveness, and overall therapeutic relevance of the dydrogesterone-letrozole combination for the treatment of endometriosis."

Journal • Endometriosis • Fibrosis • Gynecology • Immunology • Inflammation • Musculoskeletal Pain • Pain • Women's Health

GuBen AnTai decoction ameliorates recurrent spontaneous abortion by suppressing excessive autophagy via EGFR/PI3K pathway modulation. (PubMed, Phytomedicine) - "GBAT may effectively inhibit excessive autophagic activation in RSA. The EGFR/PI3K pathway plays an important role in its therapeutic efficacy. Thus, GBAT is a promising candidate for alleviating RSA-induced miscarriage."

Journal

DYG-GONA: rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Centrum Clinic IVF Center | Not yet recruiting ➔ Recruiting

Enrollment open • Gynecology

Menopausal hormone treatment and breast cancer. (PubMed, Lancet Diabetes Endocrinol) - "Micronised progesterone and dydrogesterone seem associated with a lower risk of breast cancer than progestins, as shown in observational or case-control studies, but no randomised study has addressed this questions. Evaluating baseline risk of breast cancer before prescription of MHT should be considered a minimum standard alongside education on risk factors that can help decrease the risk of breast cancer with or without using MHT. This Review synthesises contemporary randomised and observational evidence, including pharmacologic distinctions, interaction with modifiable risk factors, and implications for better shared decision-making for women considering MHT."

Journal • Review • Breast Cancer • Gynecology • Oncology • Solid Tumor

DYG-GONA: rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study (clinicaltrials.gov) - P=N/A | N=300 | Not yet recruiting | Sponsor: Centrum Clinic IVF Center

New trial • Gynecology

Dydrogesterone versus levonorgestrel-releasing intrauterine system for abnormal uterine bleeding: a propensity score-matched analysis of long-term efficacy and recurrence. (PubMed, Gynecol Endocrinol) - "Dydrogesterone effectively manages nonstructural etiologies but carries higher systemic adverse event rates. Treatment selection should be etiology-guided, balancing immediate symptom control versus recurrence prevention and individualized safety considerations."

Clinical • Journal • Retrospective data • Endometriosis • Gynecology • Obstetrics • Women's Health

Shoutai Wan improves endometrial decidualization by regulating BRD4 to activate Wnt4/β-catenin signaling pathway (PubMed, Zhongguo Zhong Yao Za Zhi) - "A mouse model of RSA was established, and CBA/J female mice were randomly divided into five groups(n=10 per group): normal group, model group, low-dose STW group(7.5 g·kg~(-1)), high-dose STW group(15 g·kg~(-1)), and dydrogesterone group(0.003 g·kg~(-1))...The results showed that STW improved endometrial decidualization in RSA mice, and enhanced the expression of PRL and IGFBP-1 proteins, thereby promoting decidualization. STW promoted endometrial decidualization by activating the Wnt4/β-catenin signaling pathway via BRD4."

Journal • BRD4 • IGFBP1 • PRL

Network meta-analysis of progestogen administration routes for luteal phase support in fresh embryo transfer IVF cycles. (PubMed, Reprod Biomed Online) - "For luteal phase support (LPS) after fresh embryo transfer in IVF, ESHRE recommends vaginal, intramuscular, subcutaneous progesterone or oral dydrogesterone. These findings, supported by sensitivity analyses excluding low-quality and older studies, suggest that oral and intramuscular progestogens may be more effective in improving IVF outcomes, but outcome differences require further studies. This study substantially advances the evidence base by integrating recent data, applying rigorous quality assessment standards and using state-of-the-art network meta-analytic methodology, contributing to refining recommendations for optimal progestogenic LPS in fresh IVF cycles."

Journal • Retrospective data • Review

Assessing dydrogesterone efficacy in endometrial protection for abnormal uterine bleeding from endometrial hyperplasia. (PubMed, Afr J Reprod Health) - "Dydrogesterone treatment following hysteroscopic surgery for females with abnormal uterine bleeding and endometrial hyperplasia demonstrates superior efficacy in endometrial protection and symptom management, without escalating adverse effects. The observed enhancements in quality of life underscore its clinical utility, suggesting dydrogesterone as a valuable therapeutic option in this clinical context."

Journal • Endometriosis • Gynecology • Women's Health